BioScrip Inc. (NASDAQ: BIOS) is the largest independent national provider of infusion and home care management solutions, with approximately 2,500 teammates and nearly 80 service locations across the U.S. BioScrip partners with physicians, hospital systems, pharmaceutical manufacturers, and skilled nursing facilities to provide patients access to post-acute care services.
In July, the US House of Representatives passed HR 3178, the Medicare Part B Improvement Act of 2017. The legislation includes, as Section 101, the Home Infusion Therapy Services Temporary Transitional Payment Act. This provision accelerates the implementation of The CURES Act Section 5014, passed in Congress in December 2016, and will result in Medicare payment for home infusion services beginning in January 2019. The company is looking forward to Senate action on this legislation.
HR-3178 TITLE I–IMPROVEMENTS IN PROVISION OF HOME INFUSION THERAPY
(Sec. 101) This bill amends title XVIII (Medicare) of the Social Security Act to temporarily provide for transitional Medicare payment with respect to certain home infusion services furnished on or after January 1, 2019. Under current law, the Center for Medicare & Medicaid Services (CMS) is required to establish a permanent payment system with respect to such services furnished on or after January 1, 2021. Read the full text here: https://www.congress.gov/bill/115th-congress/house-bill/3178/text#toc-HDEE7CD18DF934C73982771FA627C42FA
The company recently announced its Second Quarter 2017 Financial Results; it reported net revenue of $218.1 million, including core product mix of 73.1% compared to 60.3% in the prior year with an Adjusted EBITDA of $10.0 million, nearly doubling from the first quarter of 2017.
As per management, the second quarter of 2017 marks an important milestone for the Company, as BIOS delivered $10 million of adjusted EBITDA, and a year over year operating cash flow improvement of $23 million, driven by core revenue growth and cost and working capital improvements, positioning it to achieve financial objectives for 2017. The improvements in EBITDA and operating cash flow, despite Cures Act reimbursement pressures, underscore the progress BIOS has made on the turnaround to date.
As far as near to medium term guidance is concerned, the Company is reiterating its prior instance of adjusted EBITDA in the range of $45.0 million to $55.0 million for full-year 2017. The Company is updating its revenue outlook for the year to a range of $815.0 million to $835.0 million, including the impact of the revised UnitedHealthcare contract.
Additionally, it expects to incur restructuring expenses in a range of $11.0 million to $12.0 million, reflecting the ongoing restructuring activity that took place in the second quarter of 2017, and further expenses anticipated in the second half of 2017 primarily related to the impact of the revised UnitedHealthcare contract.
BioScrip Inc. is being covered by a number of analysts. Recently, 3 rated the stock as Buy, 4 rated Outperform, 0 rated Hold, 0 gave an Underperform and 0 rated sell. With the recent developments, we believe the company stock is categorized as ‘BUY’. The company is reflecting reasonable bullish signs and has a medium-term average price target of $3.41 from analysts.
____________________________________________
Limited Time Offer VIP Mobile Alerts
***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our VIP – SMS/text alert service for free, simply text the word “Traders” to the phone number “25827” from your cell phone***
____________________________________________
Description:
BioScrip, Inc. is the largest independent national provider of infusion and home care management solutions, with approximately 2,500 teammates and nearly 80 service locations across the U.S. BioScrip partners with physicians, hospital systems, pharmaceutical manufacturers, and skilled nursing facilities to provide patients access to post-acute care services.
BioScrip operates with a commitment to bring customer-focused pharmacy and related healthcare infusion therapy services into the home or alternate-site setting. By collaborating with the full spectrum of healthcare professionals and the patient, BioScrip provides cost-effective care that is driven by clinical excellence, customer service, and values that promote positive outcomes and an enhanced quality of life for those it serves.
Background of the Company:
BioScrip came about in 2005 through a merger between Chromined Inc. and MIM Corporation. Chromined was founded in 1985 turned public in 1992. The company focused on the distribution of infusible medications to patients with special conditions. MIM Corp also focused on enhancing the quality of patient life through pharmacy benefit and healthcare solutions.
Home Infusion Market Overview:
Expanding Home Infusion Market: Attractive Market Growth + Significant Site of Care Opportunity
Global market for Home infusion is estimated at $20B. Out of which, U.S. market is growing organically by 5%-7%. From a competitive landscape perspective; the home infusion market is highly fragmented with 4 large national providers.
Therefore, the industry has significant consolidation opportunities with 800+ individual small-scale infusion companies in the U.S. Hospital systems, physicians, and skilled nursing centers.
BioScrip Footprint and Overview
- Largest independent home infusion provider
- Nearly 80 locations Servicing all 50 states 68 Infusion Pharmacies/ Ambulatory Infusion Suites 10 Reimbursement Centers
- Over 2,000 field personnel
- 500,000 unique visits/year (35,000/month)
- 131,799, patients serviced
Key Stock Influences
- Widespread acceptance of the company’s services could be a catalyst.
- The US Senate passage of HR-3178 could be a catalyst for the company
- Further improvement in company’s operating and market risk profile could be a medium-term catalyst. The full-fledged impact of company’s cost reduction & resource optimization initiatives is yet to be seen.
- Notwithstanding recent improvements, BioScrip’s capital structure is still leveraged, which could indicate a need for additional funding.
- BIOS’ ability to maintain its liquidity and financial flexibility to fund its incremental capital requirements. Also, any additional equity raise is exposed to significant dilution risk.
- The company’s business risk profile is impinged by significant competitive pressure. Although BioScrip is making an effort to improve its operating margin through financial improvement initiatives, it is still facing challenges in achieving a competitive operating margin.
Second Quarter 2017 Financial Results
– Net revenue of $218.1 million, including core product mix of 73.1% compared to 60.3% in the prior year
– Net loss from continuing operations of $28.7 million, compared to $8.3 million in the prior year, reflecting increased non-cash expenses and interest
– Adjusted EBITDA of $10.0 million, nearly doubling from the first quarter of 2017
– Operating Cash Flow of $6.5 million, reflecting $23 million of operational and working capital improvements over the prior year
– Liquidity of $50.5 million, including $40.5 million of cash, compared to $16.0 million at March 31, 2017
– Restructuring expenses of $3.9 million, primarily costs related to the ongoing optimization of the Company’s workforce
– The Company reaffirms EBITDA guidance and updates revenue guidance
Stock Performance:
On Friday, September 8th, 2017, BIOS shares declined by (4.58%) to $2.71 on an average volume of 1.82 million exchanging hands. Market capitalization is $308.97 Million. The current RSI is 40.92
In the past 52 weeks, shares of BIOS have traded as low as $0.98 and as high as $3.43
At $2.71, shares of BIOS are trading below their 50-day moving average (MA) at $2.88 and above their 200-day MA at $1.96
The present support and resistance levels for the stock are at $2.63 and $2.84 respectively.
Disclaimer
Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.
Traders News Source has not been compensated for this report by anyone and the opinions if any are that of the author Vikas Agrawal, CFA. Author’s Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I, wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in the article.
This web site, published by TNS LLC, and is an investment newsletter that is built on the premise of assisting individual investors in learning about investing. Our goal as publishers of financial information is to provide research and analysis of investments to our subscribers. TNS LLC does not give buy or sell recommendations. We do purchase distribution rights from analyst, financial writers and bloggers for a fee that may be licensed to issue price targets and recommendations. Furthermore, we encourage you to speak to a licensed professional prior to making an investment in any type of publicly traded security.
We do sell advertising to other companies including brokerage firms, web sites, publicly traded issuers, investor relations firms, and investment publications, among others. TNS LLC makes no warranty as to the policies of these organizations, and in no way endorses their offers, services, or the content of their advertisements.
When an advertiser is a publicly traded company or a third party acting on behalf of a public company, we fully disclose all compensation in the email advertisement. Such disclosure is included in a disclosure statement in each of the advertisements sent via email.
17B Disclosure
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.
PLEASE NOTE WELL: TNS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operator’s owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D.
TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur.
Understand there is no guarantee past performance will be indicative of future results. In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.
